Volume 7.44 | Nov 12

Mammary Cell News 7.44 November 12, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
 
TOP STORY
Blood Test Detects when Hormone Treatment for Breast Cancer Stops Working
Scientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment. They found that the test could detect mutations to the estrogen receptor gene ESR1–which conveys resistance to hormone treatment–specifically in women treated with aromatase inhibitors. [Press release from The Institute of Cancer Research discussing online prepublication in Science Translational Medicine] Press Release | Abstract
FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer
Researchers investigated the role of amphiregulin in breast cancer cell proliferation using human tissue samples and tumor xenografts in mice. [Cancer Res] Abstract

The Ascidian Natural Product Eusynstyelamide B Is a Novel Topoisomerase II Poison that Induces DNA Damage and Growth Arrest in Prostate and Breast Cancer Cells
The authors investigated the mechanism of action of eusynstyelamide B in cancer cell lines of the prostate and breast. [Oncotarget] Full Article

Activation of the Farnesoid X-Receptor in Breast Cancer Cell Lines Results in Cytotoxicity but Not Increased Migration Potential
Investigators showed that activation of the nuclear receptor arnesoid x-receptor, either by its endogenous ligand chenodexoycholic acid or the synthetic GW4064, leads to cell death in four breast cancer cell lines with distinct phenotypes: MCF-10A (normal), MCF-7 (receptor positive), MDA-MB-231 and MDA-MB-468 (triple negative). [Cancer Lett] Abstract

An EGFR/Src-Dependent β4 Integrin/FAK Complex Contributes to Malignancy of Breast Cancer
The authors demonstrated physical and functional interactions between β4 integrin and focal adhesion kinase (FAK) that influence breast cancer malignancy. [Sci Rep] Full Article

Exosomes Decrease Sensitivity of Breast Cancer Cells to Adriamycin by Delivering MicroRNAs
Scientists explored the relevance of exosome-mediated microRNA (miRNA) delivery in resistance transmission of adriamycin (adr)-resistant breast cancer (BCa) sublines. They demonstrated the selective packing of miRNAs within the exosomes derived from adr-resistant BCa cells. [Tumour Biol] Abstract

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
Investigators showed that PIK3CA mutations and PI3K/AKT pathway activation are common events in triple negative breast cancer. [PLoS One] Full Article

A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells
Researchers report a rationally designed nanobody activation immunotherapeutic that selectively redirects anti-dinitrophenyl antibodies to the surface of HER2-positive breast cancer cells, resulting in their targeted destruction by antibody-dependent cellular cytotoxicity. [Chembiochem] Abstract

CLINICAL RESEARCH

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
Researchers investigated the clinical value of estrogen-related receptor alpha (ERRα) in randomized cohorts of tamoxifen-treated and adjuvant-untreated patients. [Clin Cancer Res] Abstract

A Phase II Randomized Study of Lapatinib in Combination with Capecitabine, Vinorelbine or Gemcitabine in Patients with HER2 Positive Metastatic Breast Cancer Who Progressed after a Taxane (LACOG 0801)
In this Phase II, multicenter study, patients with HER2 positive metastatic breast cancer progressing after taxane were randomized between lapatinib 1250 mg in combination with: C 2000 mg/m2 days 1 to 14, vinorelbine 25 mg/m2 days 1 and 8 or gemcitabine 1000 mg/m2 days 1 and 8, every 21 days. [Clin Breast Cancer] Abstract

Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
 
REVIEWS
Dynamic Regulation of Stem Cell Specification and Maintenance by Hypoxia-Inducible Factors
Stem cells are often localized to hypoxic niches within tissues and hypoxia inducible factors (HIFs) play key roles in the maintenance of pluripotent and multipotent stem cells, as well as cancer stem cells, which are also known as tumor-initiating cells. HIF inhibitors target cancer stem cells and improve the responses to angiogenesis inhibitors and cytotoxic chemotherapy in mouse models of breast cancer. [Mol Aspects Med] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
INDUSTRY NEWS
BriaCell Receives FDA Authorization to Initiate Phase I/IIa Trial of Cell-Based Immunotherapy BriaVax™ in Advanced Breast Cancer Patients
BriaCell Therapeutics Corp announced that the U.S. Food and Drug Administration (FDA) has given final clearance for the company’s investigational new drug application to initiate a Phase I/IIa clinical trial of BriaVax™. [BriaCell Therapeutics Corp (Marketwired L.P.)] Press Release

GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
GSK and Merck announced the initiation of a Phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda® in patients with locally advanced, recurrent or metastatic solid tumor(s) that have progressed after standard treatment. [GlaxoSmithKline plc] Press Release

From our sponsor:
Webinar: Neural Stem Cell Culture Systems – Neurosphere vs. Adherent Monolayer Culture.
Watch now.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Cell Culture 2016
February 2-4, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Cancer Biologist (Wake Forest Baptist School of Medicine)

NEW Postdoctoral Research Fellow – Ovarian and Breast Cancer (Fred Hutchinson Cancer Research Center)

Academic Breast Pathologist (Beth Israel Deaconess Medical Center)

Group Leader Position – Cancer Research (Oslo University Hospital)

Higher Scientific Officer – Breast Cancer Research (Institute of Cancer Research)

Postdoctoral Fellow – Metastatic Breast Cancer (Purdue University Center for Cancer Research)

Biological Imaging Scientist – 3D Cellular Models of Organs and Disease (University of Pittsburgh Drug Discovery Institute)

Postdoctoral Fellow – Tumor Dormancy (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Fellow – Metastatic Breast Cancer (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us